Recommended Content:
Coronavirus and the COVID-19 Vaccine | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts
The COVID-19 vaccine has been mandated across the Department of Defense and despite its demonstrated effectiveness and safety, a host of myths have left some Airmen and Guardians hesitant to receive it. While social media posts and some news outlets may make it harder to keep up with what is fact or fiction, the science is clear...approved COVID-19 vaccines work.
Here is a breakdown of the most common myths surrounding COVID-19 vaccines, and the facts behind each myth:
Myth: COMIRNATY is not the same as the PFIZER-BIONTECH COVID-19 vaccine.
Truth: It is common for vaccine names to change after receiving full Food and Drug Administration approval for branding purposes. COMIRNATY and Pfizer-BioNTech are biologically and chemically the same vaccine. The FDA approved Pfizer-BioNTech for licensing and branding as COMIRNATY August 23 for people 16 years and older. Critically, the Emergency Use Authorization for Pfizer-BioNTech COVID-19 vaccine continues and covers the 12-15 year old population.
In accordance with FDA guidance, COMIRNATY has the same formulation and can be used interchangeably with the FDA-authorized Pfizer-BioNTech COVID-19 vaccine. Providers can use doses distributed under the EUA, to administer the vaccination series as if the doses were the licensed vaccine.
Myth: There were no people of color involved or represented in the research or development of the vaccine.
Truth: COVID-19 has taken a heavy and disproportionate toll on people of color, particularly Black adults. Historically, people of color have been underrepresented in clinical trials. Therefore, ensuring racial and ethnic diversity in clinical trials for development of COVID-19 vaccines has been particularly important. Diversity within clinical trials for a COVID-19 vaccine also ensures safety and effectiveness across populations. Findings show that Pfizer-BioNTech vaccine safety and efficacy were similar for people of color and white participants.
The FDA offered nonbinding recommendations that strongly encouraged the enrollment of populations most affected by COVID-19, specifically racial and ethnic minorities. Both Pfizer and Moderna worked to ensure that people of color were included in their trials, with Moderna even slowing down enrollment to enroll more racial and ethnic minorities. There have also been efforts on the community side. Historically Black colleges and universities participated in COVID-19 vaccine trials and encouraged participation among their communities. The purposeful encouragement to increase racial and ethnic groups in these trials have achieved greater diversity than many previous trials for other drugs.
Myth: The COVID-19 vaccine can cause problems with breast tissue and lead to breast cancer.
Truth: There is no evidence that COVID-19 vaccines cause problems with breast tissue or would lead to breast cancer. The mRNA vaccines are processed by your body near the injection site and activate immune system cells that then travel through the lymph system to nearby lymph nodes. In this manner, an individual may experience swelling under the arm where the vaccine was administered due to swelling of the lymph node. The vaccines are not affecting hormone levels, nor are they traveling throughout the body or affecting other body organs, such as breast tissue. Swollen lymph nodes can show up in a mammogram even if women can't feel them. Hence, the Society of Breast Imaging recommends women delay any routine mammography scheduled within four weeks after their most recent COVID-19 vaccination.